Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Memphasys Limited is an Australian reproductive biotechnology company specializing in the development of innovative medical devices, diagnostics, and media designed to address reproductive challenges in both humans and animals. Its core mission is to advance assisted reproductive technology (ART) through patented solutions, with the flagship Felix System standing out as a rapid, gentle, and automated sperm separation device for use in IVF procedures. The Felix device employs electrophoresis and specialized membranes to ensure the efficient isolation of high-quality sperm, minimizing contaminants and improving ART outcomes. In addition to Felix, Memphasys’s pipeline features products such as RoXsta, a diagnostic platform for assessing oxidative stress in semen and other fluids, and AI-Port, which preserves livestock semen viability at ambient temperatures, supporting animal breeding industries. The company’s integrated approach spans device engineering, in vitro diagnostics, and specialty biological media, positioning it at the forefront of reproductive health innovation. Memphasys plays a significant role in the healthcare technology sector, driving progress in fertility science and supporting both clinical and agricultural reproductive technologies.